Common Medicines For Kidney Cancer Damage The Protein Structure – Part 2 of 3
Bevacizumab belongs to a class of drugs known as angiogenesis inhibitors, which lessen the formation of new blood vessels around tumors. Avastin (bevacizumab), manufactured by Genentech, was recently approved to treat the most common type of kidney cancer.
In 2009, the US Food and Drug Administration approved the use of Avastin in concert with interferon-alfa, an immunotherapy drug, to present renal cell carcinoma that has spread to other organs in the body. A phase III trial found that the dope combination increased progression-free survival time by approximately five months, compared to use of interferon-alfa alone. The study wasn’t able to determine whether the dual treatment extended patients’ lives, according to the American Cancer Society.